盐酸万古霉素(Vancomycin Hydrochloride) - 药物靶点：Peptidoglycan_在研适应症：艰难梭菌腹泻，睑缘炎，结膜炎_专利_临床

概要

基本信息

药物类型

化学药

别名

VCM、Vancomycin hydrochloride (JP17/USP)、バルデナフィル塩酸塩水和物

+ [25]

靶点

Peptidoglycan

作用方式

抑制剂

作用机制

肽聚糖抑制剂、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

OHKURA Pharmaceutical Co., Ltd.Mylan Laboratories Ltd.Baxter Healthcare Corp.

+ [6]

非在研机构

Savara, Inc.

权益机构

Eli Lilly & Co.Iroko Pharmaceuticals, Inc.Merus Labs International, Inc.

+ [7]

最高研发阶段批准上市

首次获批日期

(1954-01-01),

革兰氏阳性细菌感染

最高研发阶段(中国)-

特殊审评孤儿药 (日本)、快速通道 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

分子式C66H76Cl3N9O24

InChIKeyLCTORFDMHNKUSG-XTTLPDOESA-N

CAS号1404-93-9

Sequence Code 525276648

关联

423

项与盐酸万古霉素相关的临床试验

NCT04993027

/ Not yet recruiting临床2期IIT

Topical Vancomycin for Infection Prophylaxis in Total Hip and Knee Arthroplasty

11% of the general population undergo total hip arthroplasty (THA) in their lifetime and 7% undergo total knee arthroplasty (TKA), with these rates expected to rise up to 50% by 2026. Periprosthetic joint infection (PJI) remains one of the most common complications, accounting for 30% of THA/TKA revision surgeries. Topical delivery of antibiotic powder may reduce the incidence of PJI but its potential drawbacks include wound healing complications, reduced osteoblast activity, third body wear, and antibiotic resistance. In THA and TKA, topical administration of vancomycin powder for the primary prevention of PJI has been studied in observational studies, but conclusions are limited due to the low incidence of PJI and high number of patients required to detect a significant difference. Investigators therefore propose a randomized controlled trial (RCT) investigating the impact of topical vancomycin compared to standard care on PJI rates following THA and TKA.
Aim: To determine whether topical vancomycin is a safe and effective intervention for the primary prevention of PJI after THA and TKA.
Study Design: This is a pilot multi-centre RCT to evaluate the study design and assess feasibility prior to implementation across Canada. Investigators aim to recruit 50 THA and 50 TKA patients.
Inclusion Criteria THA or TKA Patients aged 18 years or older Patients must complete 1 year follow-up Exclusion Criteria Patients undergoing surgery for inflammatory arthritis, post-traumatic arthritis, or avascular necrosis History or septic arthritis based on history or synovial aspirate Prior major operation on the affected joint Current immunosuppressive medications Vancomycin allergy or history of a vancomycin-related complication Recruitment: surgeons introduce study to the patients, research staff will conduct recruitment.
Intervention: Patients will be randomized preoperatively and remain blinded to their treatment arm. Patients allocated to the control group will have all standard care infection prophylaxis interventions. Patients allocated to the vancomycin group will undergo all the standard care measures in addition to 1g of powdered vancomycin applied to the wound.
Follow-up: Patients will complete follow-up at 2 weeks, 6 weeks, 3 months, 6 months, and 1 year visits.
Primary outcome: PJI in the same joint. Secondary outcome: PJI in THA and TKA subgroups:
Reoperation on the same joint Superficial and non-infectious wound complications All complications

开始日期2025-12-30

申办/合作机构

University of Calgary

NCT06954129

/ Not yet recruiting临床4期IIT

Markers of Nephrotoxicity During Treatment With Antibiotic Combinations: A Pragmatic Clinical Trial

Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP). Although these regimens have similar effectiveness, recent observational evidence suggests they may differ in terms of the risk for acute kidney injury (AKI). Interpretation of existing evidence is complicated by the limitations of creatinine, the standard biomarker used to monitor kidney function, which has poor sensitivity and specificity for drug induced AKI. To address this important knowledge gap, the investigators propose to conduct a pragmatic, open-label, non-inferiority trial that will examine the comparative risk of AKI between these standard-of-care antibiotic combinations using sensitive and specific markers of drug-induced AKI. We hypothesize that the regimen of VN in combination with PT (VN+PT) is noninferior to the regimen of VN in combination with CP (VN+CP) in terms of AKI risk.

开始日期2025-10-01

申办/合作机构

University of Pennsylvania

NCT06794944

/ Not yet recruiting临床4期IIT

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients with Inflammatory Bowel Disease

This is a randomized, double-blind study to assess the safety and efficacy of fidaxomicin compared to vancomycin for decolonization of C. difficile in IBD patients. A total of 60 patients who meet eligibility criteria will be randomized 1:1 to either the fidaxomicin or vancomycin arm. The vancomycin arm will receive a dose of 125 mg PO q 6 hours for 10 days. The fidaxomicin arm will receive 200 mg PO BID for 10 days. In order to ensure blinding, both antibiotics will be concealed in opaque 00 capsule shells. In addition, those in the fidaxomicin arm will receive 2 placebo capsules so that all participants will receive 4 capsules daily for 10 days. Microbiome assessment and C. difficile testing will be performed at baseline, day 5, day 10, and weeks 4, 8, and 26.

开始日期2025-09-01

申办/合作机构

The Brigham & Women's Hospital, Inc.

100 项与盐酸万古霉素相关的临床结果

登录后查看更多信息

100 项与盐酸万古霉素相关的转化医学

登录后查看更多信息

100 项与盐酸万古霉素相关的专利（医药）

登录后查看更多信息

57,754

项与盐酸万古霉素相关的文献（医药）

2025-12-31·Gut Microbes

Clostridioides difficile binary toxin CDT induces biofilm-like persisting microcolonies

Article

作者: Kim, Minhee ; Lejal, Emilie ; Gobaa, Samy ; Crouzols, Aline ; Altamirano-Silva, Pamela ; Dupuy, Bruno ; Chamorro-Rodriguez, Susan ; Hunault, Lise ; Tinevez, Jean-Yves ; Groussard, Déborah ; Peltier, Johann ; Meza-Torres, Jazmin ; Mary, Héloïse ; Chassaing, Benoit

Clinical symptoms of Clostridioides difficile infection (CDI) range from diarrhea to pseudomembranous colitis. A major challenge in managing CDI is the high rate of relapse. Several studies correlate the production of CDT binary toxin by clinical strains of C. difficile with higher relapse rates. Although the mechanism of action of CDT on host cells is known, its exact contribution to CDI is still unclear. To understand the physiological role of CDT during CDI, we established two hypoxic relevant intestinal models, Transwell and Microfluidic Intestine-on-Chip systems. Both were challenged with the epidemic strain UK1 CDT⁺ and its isogenic CDT^- mutant. We report that CDT induces mucin-associated microcolonies that increase C. difficile colonization and display biofilm-like properties by enhancing C. difficile resistance to vancomycin. Importantly, biofilm-like microcolonies were also observed in the cecum and colon of infected mice. Hence, our study shows that CDT induces biofilm-like microcolonies, increasing C. difficile persistence and risk of relapse.

2025-12-31·Journal of Pharmaceutical Policy and Practice

Pharmacist-led antibiotic interventions in infectious disease patients: a Pakistani tertiary care antimicrobial stewardship study

Article

作者: Ur Rehman, Naeem ; Maqbool, Sumeira ; Arif, Mehreen ; Hassan, Ali

BackgroundAntibiotics are widely used medications among infectious disease patients; therefore, proper monitoring and assessment are critical for ensuring rational use. Antimicrobial stewardship addresses the rational and appropriate use of antibiotics, which reinforces overall health outcomes. Ongoing antimicrobial resistance scenarios are an alarming condition for healthcare, necessitating continued practice of such assessments.ObjectivesTo evaluate the use of antibiotics in patients with infectious diseases, implement and evaluate clinical pharmacy interventions that adhere to antimicrobial stewardship protocols.MethodsA before and after study was designed to evaluate clinical pharmacy and antimicrobial stewardship interventions for infectious disease patients at a tertiary care hospital in Lahore. A Performa was designed for manual data collection. Study first identified the signal of error, implemented intervention and noted post-interventional followups.Results102 infectious disease cases were analyzed in total and proposed 136 interventions. Physicians accepted 66% of the interventions (90) and rejected the remaining ones as unjustified. The most accepted intervention was the spectrum-based choice (n = 30), followed by de-escalation of dose (n = 17). Use of ceftriaxone was very high (54 Pt.), followed by vancomycin (30 Pt.).ConclusionAntimicrobial stewardship programmes are critical for any institution's proper health care system. It ensures proper antibiotic outflow to patients, thereby improving their health status. The role of pharmacists in establishing an AMS in a hospital setting is a highly commendable activity that enhances healthcare collaboration and outcomes. Clinical pharmacists should implement such activities to improve patient care.

2025-12-31·Annals of Medicine

Vancomycin wound penetration in open-heart surgery patients receiving negative pressure wound therapy for deep sternal wound infection

Article

作者: Kacířová, Ivana ; Ďuricová, Jana ; Šištík, Pavel ; Kolek, Martin ; Motyka, Oldřich ; Juřica, Jan ; Brozmanová, Hana ; Kaňková, Klára

INTRODUCTIONIt is hypothesized that systemically administered antibiotics penetrate wound sites more effectively during negative pressure wound therapy (NPWT). However, there is a lack of clinical data from patients who receive NPWT for deep sternal wound infection (DSWI) after open-heart surgery. Here, we evaluated vancomycin penetration into exudate in this patient group.PATIENTS AND METHODSFor this prospective observational study, we enrolled 10 consecutive patients treated with NPWT for post-sternotomy DSWI. On the first sampling day, serum and exudate samples were synchronously collected at 0 (pre-dose), 0.5, 1, 2, 3 and 6 h after vancomycin administration. On the following three consecutive days, additional samples were collected, only before vancomycin administration.RESULTSThe ratio of average vancomycin concentration in wound exudate to in serum was higher for free (unbound) (1.51 ± 0.53) than for total (bound + unbound) (0.91 ± 0.29) concentration (p = 0.049). The percentage of free vancomycin was higher in wound exudate than serum (0.79 ± 0.19 vs. 0.46 ± 0.16; p = 0.04). Good vancomycin wound penetration was maintained on the following three days (vancomycin trough exudate-to-serum concentration ratio > 1). The total hospital stay was significantly longer in patients with DSWI (46 ± 11.6 days) versus without DSWI (14 ± 11.7 days) (p < 0.001). There was no in-hospital or 90-day mortality. Two patients experienced late DSWI recurrence. All-cause mortality was 4.8% during a median follow-up of 2.5 years.CONCLUSIONVancomycin effectively penetrates wound exudate in patients receiving NPWT for DSWI after open-heart surgery.The protocol for this study was registered at ClinicalTrials.gov on July 16, 2024 (NCT06506032).

487

项与盐酸万古霉素相关的新闻（医药）

2025-05-04

·米内网

青峰医药厉害了！拿下19个重磅品种，8款1类新药、12个新品来袭，猛攻2大千亿市场

精彩内容近日，青峰医药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评。2024年至今，公司有18个品种获批生产并视同过评（3个首仿），目前总过评品种数已增加至44个（10个首家/独家），7大“光脚”品种备战第十一批集采。近年来，青峰医药以研发驱动为发展战略，2款1类新药获批上市，还有8款1类新药在国内处于申请临床及以上阶段；12个品种以新注册分类申报在审，其中有7个暂无首仿（含剂型首仿）获批。大丰收！拿下1款1类新药、3个首仿3月25日，青峰医药自主研发的化药1类新药玛舒拉沙韦片(GP681)获批上市，适用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。据悉，该药是国内获批的首款国产流感病毒聚合酶酸性蛋白(PA)抑制剂，同时也是江西首个获批上市的化学药1类创新药。3月18日及11日，青峰医药申报的仿制药吡仑帕奈口服混悬液、口服溶液用盐酸万古霉素获批生产并视同过评，均为国内首仿+首家过评。米内网数据显示，2024年中国三大终端六大市场（统计范围详见本文末）万古霉素销售额超过20亿元。以审评结论日期计，2024年以来青峰医药在国内有1款1类新药获批上市，18个品种获批生产并视同过评，涉及抗肿瘤、抗癫痫、抗病毒、抗血栓形成、高血压、咳嗽感冒、抗细菌、抗贫血等细分领域。2024年以来青峰医药获批上市的品种来源：米内网中国申报进度（MED）数据库18个品种2024年在中国三大终端六大市场的销售额合计超过130亿元，其中硝苯地平控释片接近50亿元，罗沙司他胶囊超23亿元，贝前列素钠片、奥拉帕利片、瑞戈非尼片等超10亿元。上述品种中，青峰医药有多个品种为国内首批获批上市，其中吡仑帕奈口服混悬液、口服溶液用盐酸万古霉素、布立西坦片为国内首仿+首家过评，吡仑帕奈片国产第2家获批，伊布替尼胶囊、罗沙司他胶囊国产第3家获批，甲磺酸艾立布林注射液国产第4家获批等。值得一提的是，美索巴莫注射液是青峰医药首个获批生产的肌肉-骨骼系统化药，硫酸镁注射液为公司首款获批生产的矿物质补充剂。米内网数据显示，近年来中国三大终端六大市场肌肉-骨骼系统药物（化药）、矿物质补充剂（化药）销售额均分别超过400亿元、200亿元。44个品种过评！7大光脚品种备战第11批集采截至目前，青峰医药有44个品种过评或视同过评，其中吡仑帕奈口服混悬液、口服溶液用盐酸万古霉素、布立西坦片、甲磺酸多沙唑嗪缓释片、拉考沙胺注射液、甲苯磺酸索拉非尼片、艾司奥美拉唑镁肠溶片、拉考沙胺片、恩替卡韦胶囊、恩替卡韦分散片等为首家或独家过评（含并列）。青峰医药过评品种来源：米内网一致性评价进度数据库44个品种涵盖9个治疗大类，集中在抗肿瘤和免疫调节剂（10个）、神经系统药物（10个）、全身用抗感染药物（8个）等治疗领域。在过往开展的国家集采中，青峰医药累计有18个品种中选，其中在第十批国采中顺利中选了7个品种。此外，目前公司还有15个过评品种暂未纳入国采，其中有7个已满足7家及以上的充分竞争条件，包括5个口服常释剂型、1个注射剂、1个缓释控释剂型。青峰医药过评但未纳入国采且已满足入围门槛的品种注：销售额低于1亿元用*代替来源：米内网综合数据库从市场规模看，罗沙司他口服常释剂型、奥拉帕利口服常释剂型2个品种2024年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售额均超过10亿元，目前分别有17家、9家企业符合申报资格。从获批日期看，贝前列素钠片为青峰医药2025年1月新获批品种，罗沙司他胶囊、奥拉帕利片、恩扎卢胺软胶囊、美索巴莫注射液均为2024年获批品种，磷酸特地唑胺片、甲磺酸多沙唑嗪缓释片为2023年获批品种，目前公司在上述7个品种中所占的市场份额均为0。8款1类新药在路上！7个品种抢首仿据悉，青峰医药以研发驱动为发展战略，聚焦未满足的临床需求，每年以不低于年销售额10%的资金投入研发，专注于高价值、差异化的药品，形成了全球化、全链条的创新研发体系。3月25日，青峰医药自主研发的化药1类新药玛舒拉沙韦片(GP681)获批上市，适用于既往健康的12岁及以上青少年和成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。III期临床研究显示，该药可有效缩短流感症状缓解时间并快速清除病毒，同时具有良好的安全性和耐受性。2023年10月，青峰医药自主研发的中药1.2类新药枳实总黄酮片获批上市，该药具有行气消积、散痞止痛的功效，适用于功能性消化不良，症见餐后饱胀感、早饱、上腹烧灼感和上腹疼痛等。据不完全统计，目前青峰医药在国内有8款1类新药处于申请临床及以上阶段，集中在抗肿瘤药、抗感染药2大治疗领域。米内网数据显示，2024年中国三大终端六大市场抗肿瘤药（化药+生物药）、全身用抗感染药（化药+生物药）市场规模均超过1000亿元。青峰医药国内部分在研1类新药来源：米内网综合数据库仿制药方面，除了已获批/主动撤回品种，目前青峰医药有12个品种以新注册分类申报上市/临床，包括4个神经系统药物、4个抗肿瘤和免疫调节剂、2个消化系统及代谢药、1个皮肤病用药、1个全身用激素类制剂(不含性激素和胰岛素)。青峰医药新分类申报且在审的品种来源：米内网中国申报进度（MED）数据库7个品种在国内暂无仿制药获批，包括利那洛肽胶囊、布立西坦口服溶液、布立西坦注射液、阿贝西利片、拉米地坦片、依伏卡塞片、瑞卢戈利片。其中，阿贝西利是礼来开发的一种周期蛋白依赖性激酶4和6(CDK4和CDK6)的抑制剂，2024年全球销售额超过53亿美元。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至4月30日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准一致性评价

2025-04-30

·PRNewswire

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: International: Click here for participant international Toll-Free access numbers About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. Acurx previously announced that it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit . Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & CEO Tel: 917-533-1469 Email: [email protected] SOURCE Acurx Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期财报快速通道合格传染病产品

2025-04-29

·医药云端工作室

27类！四川公布《抗菌药临床分级管理目录（2025版）》，这些品种不纳入目录

编辑：子非鱼4月28日，四川省卫健委发出《关于印发《四川省抗菌药物临床应用分级管理录(2025年版)》的通知》（川卫办医政便函〔2025】25号），公布新版抗菌药临床分级管理目录（2025年版），本目录自印发之日起施行，原《2022年版)》同时废止。该通知指出，为进一步规范全省抗菌药物合理应用，结合我省实际情况:我委委托四川省抗菌药物合理使用专家委员会对《四川省抗菌药物临床应用分级管理目录(2022年版)》进行修订，制定了《四川省抗菌药物临床应用分级管理目录(2025年版)》，现予印发，请遵照执行。各级卫生健康行政部门和医疗机构要高度重视抗菌药物临床应用管理工作，切实履行主体责任，将抗菌药物分级管理纳入医疗质量安全核心制度。各医疗机构在确定本单位抗菌药物临床应用分级管理目录时，应本着从严管理的原则，不得自行下调管理级别。2025年版目录共收录27类抗菌药物，包括四环素类、氯霉素类、青霉素类复方制剂、第1-5代投保菌素等。这些抗菌药物按临床管理需要分为非限制使用级、限制使用级、特殊使用级等。某些药物并不纳入该目录管理范围（详细内容见文末“备注”）《通知》同时也备注指出：备注:1.本目录所列抗菌药物为治疗由细菌(含支原体、衣原体立克次体、螺旋体等)和真菌所致感染性疾病的药物，但不包括外用及局部作用几乎不全身吸收的抗菌药物(包括口服几乎不全身吸收的抗菌药物[如:利福昔明、制霉菌素口服制剂、万古霉素口服制剂等]、抗菌药物雾化吸入制剂)、抗结核病药、抗风病药、抗病毒感染药、抗寄生虫感染药以及具有抗菌作用的中药制剂。2.根据《关于进一步加强抗菌药物临床应用管理工作的通知》(国卫办医发〔2015】42号)中对抗菌药物临床应用管理评价指标及要求的规定，标注“*”的抗菌药物品种，不计入医疗机构药品采购目录中抗菌药物品种数。3.链霉素、利福平(口服)目前临床主要用于抗结核治疗视为抗结核病药，不纳入本目录。4.标注“#”的伊曲康唑胶囊、特比萘芬、克霉唑、咪康唑,临床多用于浅部真菌感染，可视为浅部抗真菌药。5.标注“★”的抗菌药物品种，原则上仅限于省内地市级及以上的三级甲等医疗机构使用(不包括地市州级以下的县、区及县级市)6.标注“▲”的抗菌药物品种，原则上仅限于省内三级甲等医疗机构、三级乙等医疗机构使用。7.本目录发布之后上市的抗菌药物，仅限于省内地市级及以上的三级甲等医疗机构使用(不包括地市州级以下的县、区及县级市)，并作为特殊使用级抗菌药物管理。关注公众号，获取可靠、专业的资讯和分析内容

微生物疗法临床研究

100 项与盐酸万古霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00926	盐酸万古霉素	J01XA01 A07AA09 S01AA28	DB00512

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
（非特异性）化脓性脑膜炎	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
关节炎	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
脓胸	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
细菌性心内膜炎	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
出血性败血症	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
肺脓肿	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
中性粒细胞减少	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
骨髓炎	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
肺炎	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
继发感染	日本	OHKURA Pharmaceutical Co., Ltd.	2004-10-22
骨和关节感染	美国	Baxter Healthcare Corp.	1993-04-29
心内膜炎	美国	Baxter Healthcare Corp.	1993-04-29
感染	美国	Baxter Healthcare Corp.	1993-04-29
下呼吸道感染	美国	Baxter Healthcare Corp.	1993-04-29
脓毒症	美国	Baxter Healthcare Corp.	1993-04-29
皮肤和皮肤结构感染	美国	Baxter Healthcare Corp.	1993-04-29
伪膜性结肠炎	日本	OHKURA Pharmaceutical Co., Ltd.	1986-04-30
腹泻	美国	ANI Pharmaceuticals, Inc.	1986-04-15
小肠结肠炎	美国	Eli Lilly & Co.	1958-01-01
革兰氏阳性细菌感染	-	-	1954-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
囊性纤维化	药物发现	加拿大	Savara, Inc.	2017-09-20
囊性纤维化	药物发现	美国	Savara, Inc.	2017-09-20
耐甲氧西林金黄色葡萄球菌感染	药物发现	加拿大	Savara, Inc.	2017-09-20
耐甲氧西林金黄色葡萄球菌感染	药物发现	美国	Savara, Inc.	2017-09-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06506032 (Pubmed \| Ann Med)	N/A	伤口感染	10	Vancomycin (Patients with Deep Sternal Wound Infection (DSWI))	齋網簾觸醖繭醖鹽觸製(壓簾顧遞壓積鑰壓顧鏇) = All-cause mortality was 4.8% during a median follow-up of 2.5 years 艱選製襯廠淵遞憲鏇衊 (鹹廠範範選壓壓艱鏇壓 ) 更多	积极	2025-12-31
NCT04247542 (CTgov)	临床2期	艰难梭菌感染	53	Ibezapolstat (ACX-362E) (Segment 2A: Ibezapolstat (ACX-362E) Open-Label Single-Arm)	膚壓壓獵繭憲淵襯鏇遞(選壓觸壓構鹹鹽餘顧構) = 膚壓衊膚鏇淵鑰繭選憲繭膚夢獵鹹顧簾膚遞齋 (築獵鹽醖顧繭蓋夢築憲, 積衊鏇繭齋廠構鏇蓋窪 ~ 範鏇繭遞築醖觸鹽繭顧) 更多	-	2025-01-17
				Ibezapolstat (Segment 2B: Ibezapolstat Arm--double-blind, Randomized, Active-controlled Clinical Segment)	憲壓鏇繭鬱蓋齋積網衊(繭餘衊齋範鹹鹽顧艱鏇) = 鹹襯鏇獵衊繭獵範糧憲鬱憲顧鹹範鬱鬱鹹製壓 (醖憲壓鏇鬱餘顧築鬱繭, 壓壓網獵蓋衊鏇選築壓 ~ 遞積憲網窪襯願網選鬱) 更多
NCT03617445 (CTgov)	临床2期	艰难梭菌感染	3	Oral Vancomycin placebo (FMT Oral Capsules/ Oral Vancomycin Placebo)	壓繭鹹鏇壓糧夢窪蓋網(鏇衊襯繭蓋夢窪廠憲齋) = 餘蓋衊窪壓窪願窪廠窪觸鏇鹽簾醖觸壓製艱齋 (齋鏇簾製鏇鏇窪鏇鏇觸, 膚鹽淵觸襯壓夢簾艱憲 ~ 蓋構觸鹹夢膚窪範醖獵) 更多	-	2025-01-09
				FMT oral placebo+Oral Vancomycin (Placebo FMT Capsules/ Active Oral Vancomycin)	壓繭鹹鏇壓糧夢窪蓋網(鏇衊襯繭蓋夢窪廠憲齋) = 衊鬱鑰願願艱壓範夢製觸鏇鹽簾醖觸壓製艱齋 (齋鏇簾製鏇鏇窪鏇鏇觸, 鑰鹹繭顧壓遞膚餘憲積 ~ 鬱獵窪遞衊鹹艱鬱壓鹹) 更多
NCT02432807 (CTgov)	临床3期	细菌性结膜炎	303	Vancomycin 1.1% (Vancomycin 1.1%)	鹹衊襯壓選願衊簾淵衊(範齋鬱鹹壓遞簾築願選) = 襯壓鹽窪餘憲構窪網齋壓衊餘遞廠願範憲鑰衊 (製鏇遞廠鑰繭夢獵積獵, 獵鹹襯壓築蓋鹹憲顧夢 ~ 艱構齋蓋醖鹽顧淵鑰觸) 更多	-	2024-10-23
				Placebo (Placebo)	鹹衊襯壓選願衊簾淵衊(範齋鬱鹹壓遞簾築願選) = 糧淵廠製餘廠網構醖餘壓衊餘遞廠願範憲鑰衊 (製鏇遞廠鑰繭夢獵積獵, 鑰願鹽憲鏇壓淵構窪醖 ~ 餘鏇艱膚繭憲積顧膚簾) 更多
NCT04775953 (CTgov)	临床2期	金黄色葡萄球菌菌血症	200	Dalbavancin (Dalbavancin)	鑰顧鹹範獵壓夢廠簾顧(鏇願觸醖鹹積壓餘餘網): Pr(Better DOOR in dalbavancin arm) = 47.70 (95% CI, 39.84 ~ 55.68) 更多	-	2024-10-22
				cefazolin+penicillin+oxacillin+Nafcillin+daptomycin+Vancomycin (Standard of Care)
IBIS (UEGW2024)	N/A	感染一线	489	Vancomycin	(範獵製繭艱獵積窪衊願) = 鑰觸鬱選範遞鏇顧獵醖廠遞積鹽簾鑰鏇獵鬱膚 (醖廠顧製繭壓觸簾鹹遞 )	积极	2024-10-13
				Metronidazole	(範獵製繭艱獵積窪衊願) = 夢製鏇醖醖鏇鏇鹽夢廠廠遞積鹽簾鑰鏇獵鬱膚 (醖廠顧製繭壓觸簾鹹遞 )
UEGW2024	N/A	艰难梭菌感染	-	Fidaxomicin	遞鹹簾遞齋餘鑰遞觸襯(遞襯夢壓獵製窪觸艱選) = 艱鬱鹽製鏇選襯獵鏇艱夢窪鑰膚窪獵餘鑰窪鹽 (艱範鑰鬱蓋遞膚餘願憲 ) 更多	-	2024-10-13
				Oral Vancomycin	遞鹹簾遞齋餘鑰遞觸襯(遞襯夢壓獵製窪觸艱選) = 鑰鹽築淵簾衊構醖糧壓夢窪鑰膚窪獵餘鑰窪鹽 (艱範鑰鬱蓋遞膚餘願憲 ) 更多
NCT04132427 (CTgov)	临床2期	胃肠道疾病 \| Pitt-Hopkins综合征	6	vancomycin, magnesium citrate, microbiota (Group A: Treatment)	遞蓋餘築範觸選夢憲觸(餘衊遞鬱鏇窪願構鏇廠) = 鏇範鏇選選鏇鹽憲夢壓鏇醖衊範餘襯蓋繭顧齋 (構鹽淵範醖築襯鏇網網, 鏇襯衊蓋觸顧願鑰糧淵 ~ 夢壓選鏇繭蓋選淵築衊) 更多	-	2024-08-26
				placebo vancomycin, real magnesium citrate, placebo microbiota (Group B: Placebo)	遞蓋餘築範觸選夢憲觸(餘衊遞鬱鏇窪願構鏇廠) = 觸鑰鬱繭鬱衊觸糧窪衊鏇醖衊範餘襯蓋繭顧齋 (構鹽淵範醖築襯鏇網網, 膚膚製鏇鬱鏇積膚獵餘 ~ 願壓願願廠獵膚壓鑰鹹) 更多
ATS2024	N/A	-	-	Pharmacist-led vancomycin consult service	醖壓鏇醖糧選夢糧壓膚(淵齋廠艱製簾願鬱膚觸) = 夢壓鏇鹽觸衊網鹽鹽築積積廠蓋繭選積製鬱衊 (製齋觸願膚鬱憲醖淵簾 ) 更多	-	2024-05-19
				Vancomycin (Standard of care)	醖壓鏇醖糧選夢糧壓膚(淵齋廠艱製簾願鬱膚觸) = 壓簾齋糧積網簾遞鏇艱積積廠蓋繭選積製鬱衊 (製齋觸願膚鬱憲醖淵簾 ) 更多
ATS2024	N/A	过敏	-	Vancomycin	顧願獵願齋醖鏇蓋網顧(願鏇網鹹網獵繭齋鬱衊) = Vancomycin induced anaphylaxis developing life-threatening disseminated intravascular coagulation and multiorgan failure resulting in sepsis 齋繭選鬱蓋構淵觸簾憲 (鬱鬱膚鹹網鏇夢夢鹹願 )	-	2024-05-19